• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
AGI
Click for more information
0.00% 82.0¢

AINSWORTH GAME TECHNOLOGY LIMITED - News & Media

Market Cap $276.1M  ! watchlist Created with Sketch. Add to my watchlist
Consumer Cyclical Resorts & Casinos

Ainsworth Game Technology Limited is an Australia-based company, which is engaged in the... Ainsworth Game Technology Limited is an Australia-based company, which is engaged in the designing, developing, manufacturing, selling and servicing of gaming machines and other related equipment and services. The Company is focused on expanding and diversifying its product offerings within both land-based and online gaming markets, including social gaming and licensed Real Money gambling markets. The Company's segments include Asia Pacific, which consists of Australia, New Zealand and Asia; North America; Latin America and Europe, and Online Gaming. The Company’s products include A-Star Curve XL, A-Star Slant Top, Grand / Royal Legacy, New Low Denomination Content, Multi Games, Xtension Link, Ainsworth Historical Horse Racing. The Company's online games include B2B Real Money Gaming (RMG) and B2B Social Casino Business. The Company's subsidiaries include AGT Pty Ltd and AGT Service Pty Ltd.More

No News & Media currently available.

(20min delay)
Last
82.0¢ 		Change
0.000(0.00%) 		Mkt cap ! $276.1M
Open High Low Value Volume
82.0¢ 82.0¢ 82.0¢ $2.135K 2.604K

Buyers (Bids)

No. Vol. Price($)
2 74 79.5¢
 

Sellers (Offers)

Price($) Vol. No.
82.0¢ 27609 1
View Market Depth
Last trade - 10.41am 02/10/2024 (20 minute delay) ?
Last
81.5¢ 		  Change
0.000 ( 1.24 %)
Open High Low Volume
81.5¢ 81.5¢ 81.5¢ 172
Last updated 10.41am 02/10/2024 ?
AGI (ASX) Chart

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
PainChek close to finding out if FDA approves its flagship app for use in dementia care PainChek (ASX:PCK) has updated the market on the progress of its De Novo submission to the US FDA for its flagship app in aged care settings.
Maximus jumps 7% as it unveils latest gold drill hits at Eagles Nest; grades up to 15g/t Maximus Resources (ASX:MXR) has unveiled its latest drilling assay results at Eagles Nest, hitting gold downhole multiple assets.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.